Trial Profile

A Phase Ib/II Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Docetaxel; Doxorubicin; Gemcitabine; Irinotecan; Paclitaxel; Vinorelbine
Indications Adenocarcinoma; Breast cancer; Ovarian cancer; Pancreatic cancer; Sarcoma; Small cell lung cancer; Solid tumours
Focus Adverse reactions
Acronyms PembroPlus

Most Recent Events

28 Jun 2018 Status changed from active, no longer recruiting to discontinued.
08 Nov 2017 Results (n=17) evaluating the safety and efficacy of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma patients, were published in the Investigational New Drugs.
08 Aug 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com